AIM： To investigate the relationships between polymorphisms of interleukin-1R receptor antagonist genes and susceptibility to chronic hepatitis B in Iran population. METHODS： Genomic DNA was extracted from the perip...AIM： To investigate the relationships between polymorphisms of interleukin-1R receptor antagonist genes and susceptibility to chronic hepatitis B in Iran population. METHODS： Genomic DNA was extracted from the peripheral blood of 80 patients with chronic hepatitis B （57 males, 23 females） aged 12-77 years （mean 36.1 ± 13.8 years） and 147 normal controls （96 males, 51 females） aged 6-75 years （mean 41 ± 18.7 years） who referred to a liver clinic of Tehran and then subjected to polymerase chain reaction （PCR） amplification. PCR products were resolved on a 3% agarose gel and stained with ethidium bromide. RESULTS： Only three of the five kinds of polymorphism （2/2, 2/4, and 4/4） were found in this study. The frequencies of 2/2, 2/4, and 4/4 were 12.5%, 17.5%, 70% respectively in chronic hepatitis B patients and 6.8%, 24.5%, and 68.7% respectively in controls. IL-1 R allele 2 was detected in 30% of chronic hepatitis B patients and in 31.3% of controls, while IL-1 R allele 4 was detected in 87.5% of chronic hepatitis B patients and in 93.2% of controls. The frequency of IL-1R alleles 2 and 4 was detected in 21.25% and 78.75% of the patients and 19.04% and 80.96% of the controls, respectively. CONCLUSION： Our results suggest that the carriage of IL-1R receptor antagonist alleles 2, 4, 6 may not play any role in the development of HBV infection. Large population-based studies are needed to investigate the role of IL-1 polymorphisms in the pathogenesis of developing chronic hepatitis B.展开更多
目的:评估H2受体拮抗剂(histamine-receptor antagonists,H2RA)应用是否增加肺炎的发生危险。方法:应用计算机检索EMBASE、CENTRAL(the Cochrane central register of con-trolledtrials)、Medline、万方数据库、中国生物医学文献数据...目的:评估H2受体拮抗剂(histamine-receptor antagonists,H2RA)应用是否增加肺炎的发生危险。方法:应用计算机检索EMBASE、CENTRAL(the Cochrane central register of con-trolledtrials)、Medline、万方数据库、中国生物医学文献数据库系统(CBM)、中国期刊全文数据库(CNKI)等,搜集公开发表的关于H2RA应用与肺炎发生危险的随机对照研究(randomized con-troled trials,RCT)。以受试者肺炎发生的相对危险度(relative risk,RR)及相应的95%置信区间(95%confidence interval,95%CI)作为效应指标进行合并统计量。各研究间的统计学异质性采用Q统计量的I2检验来分析,双侧P>0.05认为各研究间不存在明显的统计学异质性,采用固定效应模型进行分析,反之采用随机效应模型进行分析。应用Egger法对发表偏倚进行量化检测。结果:共有18篇研究符合纳入标准,2974例受试者,H2RA组1508例,对照组1466例。Me-ta分析显示,H2RA可增加受试者肺炎的发生风险(RR=1.22,95%CI=1.05～1.41,Z=2.61,P=0.009);亚组分析,H2RA与安慰剂相比,使受试者的肺炎风险增加21%(RR=1.21,95%CI=1.02～1.45,Z=2.17,P=0.03),H2RA与硫糖铝相比并不增加受试者肺炎的发生风险(RR=1.22,95%CI=0.93～1.60,Z=1.45,P=0.148)。结论:H2RA的应用可能是肺炎发生的一个危险因素。展开更多
文摘AIM： To investigate the relationships between polymorphisms of interleukin-1R receptor antagonist genes and susceptibility to chronic hepatitis B in Iran population. METHODS： Genomic DNA was extracted from the peripheral blood of 80 patients with chronic hepatitis B （57 males, 23 females） aged 12-77 years （mean 36.1 ± 13.8 years） and 147 normal controls （96 males, 51 females） aged 6-75 years （mean 41 ± 18.7 years） who referred to a liver clinic of Tehran and then subjected to polymerase chain reaction （PCR） amplification. PCR products were resolved on a 3% agarose gel and stained with ethidium bromide. RESULTS： Only three of the five kinds of polymorphism （2/2, 2/4, and 4/4） were found in this study. The frequencies of 2/2, 2/4, and 4/4 were 12.5%, 17.5%, 70% respectively in chronic hepatitis B patients and 6.8%, 24.5%, and 68.7% respectively in controls. IL-1 R allele 2 was detected in 30% of chronic hepatitis B patients and in 31.3% of controls, while IL-1 R allele 4 was detected in 87.5% of chronic hepatitis B patients and in 93.2% of controls. The frequency of IL-1R alleles 2 and 4 was detected in 21.25% and 78.75% of the patients and 19.04% and 80.96% of the controls, respectively. CONCLUSION： Our results suggest that the carriage of IL-1R receptor antagonist alleles 2, 4, 6 may not play any role in the development of HBV infection. Large population-based studies are needed to investigate the role of IL-1 polymorphisms in the pathogenesis of developing chronic hepatitis B.
